Evidence map›Paper›PMID 25263953›Full record

Trial reportImmunology letters2014

Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort.

Rose Nabatanzi, Lois Bayigga, Isaac Ssinabulya, Agnes Kiragga, Andrew Kambugu, Joseph Olobo, Moses Joloba, Moses R Kamya, Harriet Mayanja-Kizza, Damalie Nakanjako

Abstract readClinical TrialComparative Study
In one paragraph

Trial report in Immunology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Rose NabatanziDepartment of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. Electronic address: rosemagala@yahoo.com.
Lois BayiggaDepartment of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. Electronic address: baylois@gmail.com.
Isaac SsinabulyaDepartment of Internal Medicine, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda. Electronic address: ssinabulyaisaac@gmail.com.
Agnes KiraggaInfectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: akiragga@idi.co.ug.
Andrew KambuguInfectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: akambugu@idi.co.ug.
Joseph OloboDepartment of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda. Electronic address: jolobo@yahoo.co.uk.
Moses JolobaDepartment of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda; Department of Internal Medicine, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda; Infectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: moses.joloba@case.edu.
Moses R KamyaDepartment of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda; Department of Internal Medicine, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda; Infectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: mkamya@infocom.co.ug.
Harriet Mayanja-KizzaInfectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: hmk@chs.mak.ac.ug.
Damalie NakanjakoDepartment of Internal Medicine, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda; Infectious Diseases Institute, Makerere University, Kampala, Uganda. Electronic address: dnakanjako@gmail.com.
Makerere University · UGInfectious Diseases Institute · UG

Funding

University of California Launching Future Leaders in Global Health Research Training ProgramD43TW009343 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIG R COHEN, Sung-Jae Lee · 2017 to 2026
$14.7M
Medical Education for Services to All Ugandans (MESAU)R24TW008886 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI SEWANKAMBO, NELSON K · 2010 to 2015
$9.2M
University of California Global Health Institute Program for Fellows and ScholarsR25TW009343 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COHEN, CRAIG R, STRATHDEE, STEFFANIE A. · 2012 to 2017
$6.4M
Training of Ugandans in Basic Research on TB and Emerging Infectious DiseasesD43TW009093 · FIC · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ELLNER, JERROLD J. · 2014 to 2023
$2.2M
FIC NIH HHS 5R24TW008886FIC NIH HHS D43 TW009093FIC NIH HHS D43 TW009343FIC NIH HHS R24 TW008886FIC NIH HHS R25 TW009343Wellcome Trust 084344
6 · The paper itself

Abstract

backgroundCD4 counts guide antiretroviral therapy (ART) initiation and prophylaxis for opportunistic infections. It is unclear whether normal CD4 counts translate to normalized immune responses among ART-treated adults. We compared antigen-specific CD4 T-cell immune responses among ART-treated adults with CD4≥500cells/μl, optimal immune responders (O-IR), and their age-matched healthy HIV-negative counterparts.

methodsIn a sample-based case-control study, cryopreserved peripheral blood mononuclear cells from 15 O-IR after 7 years of ART and 15 healthy controls, were analyzed for CD4+ T-cell proliferation using CFSE dye and cytokine production.

resultsCD4 T-cell proliferation, upon stimulation with PPD and pneumococcal polysaccharide antigen, was lower among O-IR relative to HIV-negative controls; p=0.016 and p=0.016 respectively. CD4 T-cell production of IL-2 was lower among O-IR relative to HIV-negative control p=0.002. CD4 T-cell proliferation upon stimulation with SEB and CMV antigens was similar among O-IR and HIV-negative controls p=0.971 and p=0.480, respectively, and so was IL-4 and IFN γ production; p=0.528 and p=0.892, respectively.

conclusionSeven years of suppressive ART caused partial CD4 T-cell function recovery in an African HIV treatment cohort, despite restoration of CD4 T-cell counts to levels≥500cells/μl. The role innate immunity in the recovery of immune function during long-term ART should be investigated to guide decisions on continued prophylaxis against opportunistic infections.

Indexed as

Cell ProliferationAdultAIDS-Related Opportunistic InfectionsAntigens, BacterialAnti-Retroviral AgentsCase-Control StudiesCD4 Lymphocyte CountCD4-Positive T-LymphocytesFemaleHIV-1HumansInterferon-gammaInterleukin-2Interleukin-4MaleMiddle AgedAntigens, BacterialAnti-Retroviral AgentsIFNG protein, humanIL2 protein, humanIL4 protein, humanInterferon-gammaInterleukin-2Interleukin-4ARTCD4 T-cell proliferationCytokine productionImmune recoverySub-Saharan AfricaUganda

Identifiers

PMID25263953
PMCPMC4537512
OpenAlexW2001949167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.